Deal leverages Fovea’s identification technology and Genzyme’s protein production and gene delivery expertise.
Fovea Pharmaceuticals and Genzyme will work together to develop gene therapies for retinal dystrophies. The collaboration will use Fovea’s selected targets and Genzyme’s gene delivery technologies.
Fovea’s high-content platform that allows the identification of new targets involved in photoreceptor degeneration in this disease. Along with Genzyme’s expertise in protein production and gene delivery, the firms hope to offer customized solutions for understanding the mechanism of the disease.
The ultimate goal is to develop new therapeutic strategies to prevent or reduce the severity of blindness.